Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

7.980 -0.200 (-2.44%)
Streaming Delayed Price Updated: 11:33 AM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions (EBS) Earnings Transcript ↗
Emergent BioSolutions (EBS) Earnings Transcript 
Via The Motley Fool
Topics Bonds Earnings
News headline image
These stocks are moving in today's session ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Here are the top movers in Thursday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Retail Traders Turn Ultra-Bullish On Emergent BioSolutions After Surprise Q3 Profit ↗
Shares of Emergent BioSolutions jumped 18% in after-hours trading after the company posted stronger-than-expected Q3 results and raised its full-year guidance. 
Via Stocktwits
News headline image
What's going on in today's after hours session ↗
The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness
Policy opinion leaders believe a biological attack is both more likely and easier to execute than a nuclear strike, highlighting concerns around bioterrorism and the nation’s readiness to respond 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Hancock Whitney's Enduring Dividend: A Beacon of Stability in Regional Banking
GULFPORT, Miss. – October 23, 2025 – Hancock Whitney Corporation (NASDAQ: HWC) has once again affirmed its steadfast commitment to shareholder returns by declaring a regular fourth-quarter 2025 common... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
From Emergent BioSolutions
Via GlobeNewswire
News headline image
3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts ↗
Discover three low P/E small-cap stocks with bullish analyst sentiment and growth potential in a lower interest rate environment 
Via MarketBeat
Topics Economy
News headline image
Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’ ↗
The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism. 
Via Stocktwits
News headline image
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.